Cargando…
Drug-resistant tuberculosis control in China: progress and challenges
BACKGROUND: China has the second highest caseload of multidrug-resistant tuberculosis (MDR-TB) in the world. In 2009, the Chinese government agreed to draw up a plan for MDR-TB prevention and control in the context of a comprehensive health system reform launched in the same year. DISCUSSION: China...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731907/ https://www.ncbi.nlm.nih.gov/pubmed/26822738 http://dx.doi.org/10.1186/s40249-016-0103-3 |
_version_ | 1782412612749754368 |
---|---|
author | Long, Qian Qu, Yan Lucas, Henry |
author_facet | Long, Qian Qu, Yan Lucas, Henry |
author_sort | Long, Qian |
collection | PubMed |
description | BACKGROUND: China has the second highest caseload of multidrug-resistant tuberculosis (MDR-TB) in the world. In 2009, the Chinese government agreed to draw up a plan for MDR-TB prevention and control in the context of a comprehensive health system reform launched in the same year. DISCUSSION: China is facing high prevalence rates of drug-resistant TB and MDR-TB. MDR-TB disproportionally affects the poor rural population and the highest rates are in less developed regions largely due to interrupted and/or inappropriate TB treatment. Most households with an affected member suffer a heavy financial burden because of a combination of treatment and other related costs. The influential Global Fund programme for MDR-TB control in China provides technical and financial support for MDR-TB diagnosis and treatment. However, this programme has a fixed timeline and cannot provide a long term solution. In 2009, the Bill and Melinda Gates Foundation, in cooperation with the National Health and Family Planning Commission of China, started to develop innovative approaches to TB/MDR-TB management and case-based payment mechanisms for treatment, alongside increased health insurance benefits for patients, in order to contain medical costs and reduce financial barriers to treatment. Although these efforts appear to be in the right direction, they may not be sufficient unless (a) domestic sources are mobilized to raise funding for TB/MDR-TB prevention and control and (b) appropriate incentives are given to both health facilities and their care providers. SUMMARY: Along with the on-going Chinese health system reform, sustained government financing and social health protection schemes will be critical to ensure universal access to appropriate TB treatment in order to reduce risk of developing MDR-TB and systematic MDR-TB treatment and management. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40249-016-0103-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4731907 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47319072016-01-30 Drug-resistant tuberculosis control in China: progress and challenges Long, Qian Qu, Yan Lucas, Henry Infect Dis Poverty Opinion BACKGROUND: China has the second highest caseload of multidrug-resistant tuberculosis (MDR-TB) in the world. In 2009, the Chinese government agreed to draw up a plan for MDR-TB prevention and control in the context of a comprehensive health system reform launched in the same year. DISCUSSION: China is facing high prevalence rates of drug-resistant TB and MDR-TB. MDR-TB disproportionally affects the poor rural population and the highest rates are in less developed regions largely due to interrupted and/or inappropriate TB treatment. Most households with an affected member suffer a heavy financial burden because of a combination of treatment and other related costs. The influential Global Fund programme for MDR-TB control in China provides technical and financial support for MDR-TB diagnosis and treatment. However, this programme has a fixed timeline and cannot provide a long term solution. In 2009, the Bill and Melinda Gates Foundation, in cooperation with the National Health and Family Planning Commission of China, started to develop innovative approaches to TB/MDR-TB management and case-based payment mechanisms for treatment, alongside increased health insurance benefits for patients, in order to contain medical costs and reduce financial barriers to treatment. Although these efforts appear to be in the right direction, they may not be sufficient unless (a) domestic sources are mobilized to raise funding for TB/MDR-TB prevention and control and (b) appropriate incentives are given to both health facilities and their care providers. SUMMARY: Along with the on-going Chinese health system reform, sustained government financing and social health protection schemes will be critical to ensure universal access to appropriate TB treatment in order to reduce risk of developing MDR-TB and systematic MDR-TB treatment and management. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40249-016-0103-3) contains supplementary material, which is available to authorized users. BioMed Central 2016-01-29 /pmc/articles/PMC4731907/ /pubmed/26822738 http://dx.doi.org/10.1186/s40249-016-0103-3 Text en © Long et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Opinion Long, Qian Qu, Yan Lucas, Henry Drug-resistant tuberculosis control in China: progress and challenges |
title | Drug-resistant tuberculosis control in China: progress and challenges |
title_full | Drug-resistant tuberculosis control in China: progress and challenges |
title_fullStr | Drug-resistant tuberculosis control in China: progress and challenges |
title_full_unstemmed | Drug-resistant tuberculosis control in China: progress and challenges |
title_short | Drug-resistant tuberculosis control in China: progress and challenges |
title_sort | drug-resistant tuberculosis control in china: progress and challenges |
topic | Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731907/ https://www.ncbi.nlm.nih.gov/pubmed/26822738 http://dx.doi.org/10.1186/s40249-016-0103-3 |
work_keys_str_mv | AT longqian drugresistanttuberculosiscontrolinchinaprogressandchallenges AT quyan drugresistanttuberculosiscontrolinchinaprogressandchallenges AT lucashenry drugresistanttuberculosiscontrolinchinaprogressandchallenges |